The estimated Net Worth of Peder Jensen is at least $210 mil dollars as of 9 November 2016. Peder Jensen owns over 8,130 units of Acorda Therapeutics Inc stock worth over $5,366 and over the last 14 years he sold ACOR stock worth over $0. In addition, he makes $205,028 as Independent Director at Acorda Therapeutics Inc.
Peder has made over 7 trades of the Acorda Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 8,130 units of ACOR stock worth $52,032 on 9 November 2016.
The largest trade he's ever made was buying 20,000 units of Acorda Therapeutics Inc stock on 14 December 2012 worth over $30,200. On average, Peder trades about 2,643 units every 57 days since 2011. As of 9 November 2016 he still owns at least 8,130 units of Acorda Therapeutics Inc stock.
You can see the complete history of Peder Jensen stock trades at the bottom of the page.
Dr. Peder K. Jensen, M.D., is an Independent Director of Acorda Therapeutics, Inc. Dr. Jensen is currently president of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen’s experience includes over 20 years with Schering-Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering-Plough with Merck in 2009. During his tenure at Schering-Plough/Merck, Dr. Jensen held a number of global senior research and development positions, including Vice President Clinical Research, SPRI, Executive Vice President Worldwide Drug Development, SPRI, and most recently Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has more than 27 years of global drug development experience across a variety of therapeutic areas, including neurology, cardiovascular, anti-infective, oncology and immunology. Over the course of his career, Dr. Jensen has been responsible for more than 40 new drug approvals worldwide, including in the U.S., Europe and Japan. Dr. Jensen is currently a member of the board of directors of Five Prime Therapeutics, Inc., where he serves as Chairperson of the Compensation and Management Development Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Research and Development Committee. Dr. Jensen previously was a member of the board of directors of BioCryst Pharmaceuticals, Inc. Dr. Jensen received his M.D. from the University of Copenhagen. Dr. Jensen’s extensive global pharmaceutical experience, combined with his specific knowledge in developing new and innovative medical treatments in many different therapeutic areas, including neurology, makes him well positioned to provide advice and guidance to the Company on its research and development programs.
As the Independent Director of Acorda Therapeutics Inc, the total compensation of Peder Jensen at Acorda Therapeutics Inc is $205,028. There are 7 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
Peder Jensen is 65, he's been the Independent Director of Acorda Therapeutics Inc since 2011. There are 7 older and 8 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Peder's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC., 2 BLUE HILL PLAZA, 3RD FLOOR, PEARL RIVER, NY, 10965.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith, eRon Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: